Alzamend Neuro, Inc.
NASDAQ:ALZN
1.73 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.051 | 0.023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.051 | -0.023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 6.455 | 7.446 | 5.201 | 1.311 | 1.069 | 3.7 | 0.323 | 0.275 | 0 |
| General & Administrative Expenses
| 3.235 | 6.682 | 7.118 | 3.641 | 3.355 | 1.309 | 0.545 | 0.943 | 0.069 |
| Selling & Marketing Expenses
| 0.247 | 0.743 | 0.018 | 0 | 0 | 0 | 0.03 | 0.331 | 0 |
| SG&A
| 3.432 | 7.425 | 7.118 | 3.641 | 3.355 | 1.309 | 0.575 | 1.273 | 0.069 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 9.887 | 14.87 | 12.32 | 4.952 | 4.424 | 5.009 | 0.898 | 1.548 | 0.069 |
| Operating Income
| -9.938 | -14.87 | -12.32 | -4.952 | -4.424 | -5.009 | -0.898 | -1.548 | -0.069 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.01 | -0.008 | -0.043 | -0.095 | 0.014 | 0.146 | -0.033 | -0.022 | 0 |
| Income Before Tax
| -9.948 | -14.878 | -12.362 | -5.047 | -4.41 | -4.862 | -0.932 | -1.57 | -0.069 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.145 | 0.043 | 0.157 | -0.014 | -0.146 | -0.898 | -0.022 | 0 |
| Net Income
| -9.948 | -14.878 | -12.405 | -5.204 | -4.396 | -4.862 | -0.932 | -1.57 | -0.069 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -14.7 | -22.89 | -20.92 | -10.75 | -9.26 | -12.4 | -1.64 | -8.18 | -0.421 |
| EPS Diluted
| -14.7 | -22.89 | -20.88 | -10.74 | -9.25 | -12.4 | -1.64 | -8.18 | -0.42 |
| EBITDA
| -9.887 | -14.847 | -12.316 | -4.95 | -4.424 | -5.009 | -0.898 | -0.022 | 0 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |